Skip to main content
. Author manuscript; available in PMC: 2023 Jun 28.
Published in final edited form as: Clin Pharmacol Ther. 2020 Jul 18;108(6):1195–1202. doi: 10.1002/cpt.1927

Table 5.

Association of combined nonsynonymous F5 variants (common and rare) with ACEI-AE and ARB-AE

F5 gene score Odds ratio (95% CI) P value
rs6025, rs200157005, rs149389480, rs143509841, rs140530655 and chr1:169529903 2.64 (1.74–4.01) 8.80 × 10−8
rs6025, rs6020, rs200157005, rs149389480, rs143509841, rs140530655 and chr1:169529903 2.21 (1.49–3.27) 6.30 × 10−9

Individuals carrying at least one deleterious variant against none were tested in a model adjusted for age, sex, center, batch, and 1–10 PC.

ACEI, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; PC, principal components.